BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer

Colon and rectal cancer (CRC) are the third most common cancer in the United States and cause approximately 50,000 deaths per year. The anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (Erbitux®) and panitumumab (Vectibix®) have been recently introduced to treat CRC. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lea, Andrew, Allingham-Hawkins, Diane, Levine, Susan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957244/
https://www.ncbi.nlm.nih.gov/pubmed/20972475
http://dx.doi.org/10.1371/currents.RRN1187
_version_ 1782188218690568192
author Lea, Andrew
Allingham-Hawkins, Diane
Levine, Susan
author_facet Lea, Andrew
Allingham-Hawkins, Diane
Levine, Susan
author_sort Lea, Andrew
collection PubMed
description Colon and rectal cancer (CRC) are the third most common cancer in the United States and cause approximately 50,000 deaths per year. The anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (Erbitux®) and panitumumab (Vectibix®) have been recently introduced to treat CRC. However, the response rate with these agents is low and they are associated with serious adverse effects. Accordingly biomarkers that can predict those patients that will respond to treatment may have clinical utility. The p.Val600Glu sequence variant (often called V600E) in the BRAF gene has been investigated as a biomarker to predict patients that will not respond to treatment with the anti-EGFR monoclonal antibodies.
format Text
id pubmed-2957244
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29572442010-10-20 BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer Lea, Andrew Allingham-Hawkins, Diane Levine, Susan PLoS Curr Evidence on Genomic Tests Colon and rectal cancer (CRC) are the third most common cancer in the United States and cause approximately 50,000 deaths per year. The anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (Erbitux®) and panitumumab (Vectibix®) have been recently introduced to treat CRC. However, the response rate with these agents is low and they are associated with serious adverse effects. Accordingly biomarkers that can predict those patients that will respond to treatment may have clinical utility. The p.Val600Glu sequence variant (often called V600E) in the BRAF gene has been investigated as a biomarker to predict patients that will not respond to treatment with the anti-EGFR monoclonal antibodies. Public Library of Science 2010-11-26 /pmc/articles/PMC2957244/ /pubmed/20972475 http://dx.doi.org/10.1371/currents.RRN1187 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Evidence on Genomic Tests
Lea, Andrew
Allingham-Hawkins, Diane
Levine, Susan
BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
title BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
title_full BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
title_fullStr BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
title_full_unstemmed BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
title_short BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
title_sort braf p.val600glu (v600e) testing for assessment of treatment options in metastatic colorectal cancer
topic Evidence on Genomic Tests
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957244/
https://www.ncbi.nlm.nih.gov/pubmed/20972475
http://dx.doi.org/10.1371/currents.RRN1187
work_keys_str_mv AT leaandrew brafpval600gluv600etestingforassessmentoftreatmentoptionsinmetastaticcolorectalcancer
AT allinghamhawkinsdiane brafpval600gluv600etestingforassessmentoftreatmentoptionsinmetastaticcolorectalcancer
AT levinesusan brafpval600gluv600etestingforassessmentoftreatmentoptionsinmetastaticcolorectalcancer

Ejemplares similares